Deepti Kantamani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Deepti Kantamani has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer L. Miatech
Baton Rouge General Internal Medicine Residency Program, Baton Rouge General Medical Center, Baton Rouge, LA, USA
1 shared publication - M. Patrick Stagg
Our Lady of the Lake Regional Medical Center, Franciscan Missionaries of Our Lady Healthcare System, Baton Rouge, Louisiana
1 shared publication - Sai Samyuktha Bandaru
Internal Medicine, Baton Rouge General Medical Center, Baton Rouge, USA
1 shared publication
Latest Publications
- Open Access
- 11 October 2021
- Published by Wiley in Case Reports in Oncological Medicine
- Vol. 2021, 1-4
Salivary Duct Carcinoma: Case Reports and Brief Review of the Literature
Salivary duct carcinoma (SDC) is an uncommon and highly aggressive tumor associated with high morbidity and mortality. According to the World Health Organization, it is an extremely rare malignancy with an estimated incidence of 1-1.2 in 1,000,000 patients. Standard treatment for SDC is wide surgical resection along with lymph node dissection followed by adjuvant radiation therapy. The role of adjuvant chemotherapy is not known. In this report, we present three cases of SDC. A 71-year-old female with T1N0M0 disease was treated with total parotidectomy, ipsilateral neck dissection, and adjuvant radiotherapy without evidence of disease recurrence at 5 months. The second is a 59-year-old female with TXN1M0 disease who was treated with total parotidectomy with ipsilateral level I-IV neck dissection and adjuvant radiotherapy without evidence of disease occurrence at 21 months. The third case is a 79-year-old male with widely metastatic disease, including brain metastases, treated with cranial irradiation, leuprolide, and lapatinib who remains under home hospice care.
- 11 October 2021
- Published by Wiley in Case Reports in Oncological Medicine
- Vol. 2021, 1-4
Open AccessSalivary Duct Carcinoma: Case Reports and Brief Review of the Literature
Salivary duct carcinoma (SDC) is an uncommon and highly aggressive tumor associated with high morbidity and mortality. According to the World Health Organization, it is an extremely rare malignancy with an estimated incidence of 1-1.2 in 1,000,000 patients. Standard treatment for SDC is wide surgical resection along with lymph node dissection followed by adjuvant radiation therapy. The role of adjuvant chemotherapy is not known. In this report, we present three cases of SDC. A 71-year-old female with T1N0M0 disease was treated with total parotidectomy, ipsilateral neck dissection, and adjuvant radiotherapy without evidence of disease recurrence at 5 months. The second is a 59-year-old female with TXN1M0 disease who was treated with total parotidectomy with ipsilateral level I-IV neck dissection and adjuvant radiotherapy without evidence of disease occurrence at 21 months. The third case is a 79-year-old male with widely metastatic disease, including brain metastases, treated with cranial irradiation, leuprolide, and lapatinib who remains under home hospice care.